Christian Born Djurhuus, M.D., PhD, BSc
Chief Science Officer
Dr. Christian Born Djurhuus brings nearly three decades of experience in cardiometabolic drug development and digital transformation. In his capacity as CSO, Dr. Djurhuus focuses on advancing Clinical Ink’s industry leading offerings supporting Cardiometabolic Drug development. In his role as EVP, Disease Management, he oversees the creation and delivery of disease management and health management products designed to support patients receiving FDA‑approved therapies, while strengthening evidence generation for biopharma partners.
Prior to joining Clinical ink, Dr. Djurhuus held multiple senior leadership roles at Novo Nordisk. Most recently, he served as Corporate Vice President, Process Transformation & Digitalization, Global Trial Portfolio, where he was responsible for decentralized clinical trial strategies and patient‑facing technologies. He previously served as Chief Digital Officer and as Vice President of Medical Science, with responsibility for global development programs in the cardiometabolic therapeutic area.
Dr. Djurhuus holds an MD in Medicine and a PhD in Endocrinology and Metabolism from the University of Aarhus, as well as a Bachelor of Science in Informatics. His background uniquely combines deep scientific expertise with digital innovation, enabling him to advance solutions that deliver meaningful impact for patients and sponsors alike.
